SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-020228
Filing Date
2020-04-30
Accepted
2020-04-30 16:55:29
Documents
8
Period of Report
2020-04-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-8k_20200427.htm 8-K 49132
2 EX-4.1 achv-ex41_69.htm EX-4.1 143827
3 EX-10.1 achv-ex101_70.htm EX-10.1 755512
4 EX-10.2 achv-ex102_45.htm EX-10.2 233178
5 EX-10.3 achv-ex103_44.htm EX-10.3 190308
6 EX-99.1 achv-ex991_18.htm EX-99.1 12292
7 GRAPHIC gb5424ec221s000001.jpg GRAPHIC 6570
8 GRAPHIC gsv4xvruapv0000001.jpg GRAPHIC 18627
  Complete submission text file 0001564590-20-020228.txt   1420604
Mailing Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101
Business Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 20836430
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences